PL2419104T3 - Kombinacje agonistów receptora 5-HT4 i inhibitorów acetylocholinoesterazy do leczenia zaburzeń poznawczych - Google Patents
Kombinacje agonistów receptora 5-HT4 i inhibitorów acetylocholinoesterazy do leczenia zaburzeń poznawczychInfo
- Publication number
- PL2419104T3 PL2419104T3 PL10713790T PL10713790T PL2419104T3 PL 2419104 T3 PL2419104 T3 PL 2419104T3 PL 10713790 T PL10713790 T PL 10713790T PL 10713790 T PL10713790 T PL 10713790T PL 2419104 T3 PL2419104 T3 PL 2419104T3
- Authority
- PL
- Poland
- Prior art keywords
- combinations
- treatment
- receptor agonists
- cognitive disorders
- acetylcholinesterase inhibitors
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16874109P | 2009-04-13 | 2009-04-13 | |
| US29255910P | 2010-01-06 | 2010-01-06 | |
| EP10713790.3A EP2419104B1 (en) | 2009-04-13 | 2010-04-12 | Combinations of 5-ht4 receptor agonists and acetylcholinesterase inhibitors for treatment of cognitive disorders |
| PCT/US2010/030760 WO2010120695A2 (en) | 2009-04-13 | 2010-04-12 | 5-ht4 receptor agonist compounds for treatment of cognitive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2419104T3 true PL2419104T3 (pl) | 2018-04-30 |
Family
ID=42237213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10713790T PL2419104T3 (pl) | 2009-04-13 | 2010-04-12 | Kombinacje agonistów receptora 5-HT4 i inhibitorów acetylocholinoesterazy do leczenia zaburzeń poznawczych |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8404711B2 (enExample) |
| EP (1) | EP2419104B1 (enExample) |
| JP (1) | JP2012523437A (enExample) |
| KR (1) | KR20120017421A (enExample) |
| CN (2) | CN102395371A (enExample) |
| AU (1) | AU2010236734B2 (enExample) |
| BR (1) | BRPI1013777A8 (enExample) |
| CA (1) | CA2758321A1 (enExample) |
| CY (1) | CY1119800T1 (enExample) |
| DK (1) | DK2419104T3 (enExample) |
| ES (1) | ES2654930T3 (enExample) |
| HR (1) | HRP20180018T1 (enExample) |
| HU (1) | HUE038141T2 (enExample) |
| IL (1) | IL215660A0 (enExample) |
| LT (1) | LT2419104T (enExample) |
| MX (1) | MX2011010782A (enExample) |
| NO (1) | NO2419104T3 (enExample) |
| PL (1) | PL2419104T3 (enExample) |
| PT (1) | PT2419104T (enExample) |
| RU (1) | RU2569056C2 (enExample) |
| SI (1) | SI2419104T1 (enExample) |
| SM (1) | SMT201800036T1 (enExample) |
| WO (1) | WO2010120695A2 (enExample) |
| ZA (1) | ZA201107490B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| HUE026815T2 (en) | 2008-11-19 | 2016-07-28 | Forum Pharmaceuticals Inc | Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| AU2010247835A1 (en) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors |
| TWI519532B (zh) | 2010-05-17 | 2016-02-01 | 艾維沃製藥公司 | （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體 |
| RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| JP6009080B2 (ja) | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ | 老化及び認知症の予防及び／または治療活性を有する乳酸菌 |
| US10874701B2 (en) | 2012-08-16 | 2020-12-29 | University-Industry Cooperation Group Of Kyung Hee University | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| RS61704B1 (sr) | 2017-05-24 | 2021-05-31 | H Lundbeck As | Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele |
| CN116585316A (zh) | 2017-06-01 | 2023-08-15 | 卫材R&D管理有限公司 | 包含pde9抑制剂的药物组合物 |
| JP7282028B2 (ja) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
| CA3069989C (en) | 2017-07-31 | 2025-05-06 | Alfasigma S.P.A. | METHODS FOR TREATING GASTROPARESIA SYMPTOMS USING VELUSETRAG |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60124730T2 (de) * | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| TWI377206B (en) | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2010
- 2010-04-12 LT LTEP10713790.3T patent/LT2419104T/lt unknown
- 2010-04-12 HR HRP20180018TT patent/HRP20180018T1/hr unknown
- 2010-04-12 AU AU2010236734A patent/AU2010236734B2/en not_active Ceased
- 2010-04-12 SI SI201031632T patent/SI2419104T1/en unknown
- 2010-04-12 PT PT107137903T patent/PT2419104T/pt unknown
- 2010-04-12 RU RU2011146032/15A patent/RU2569056C2/ru not_active IP Right Cessation
- 2010-04-12 CA CA2758321A patent/CA2758321A1/en not_active Abandoned
- 2010-04-12 HU HUE10713790A patent/HUE038141T2/hu unknown
- 2010-04-12 SM SM20180036T patent/SMT201800036T1/it unknown
- 2010-04-12 ES ES10713790.3T patent/ES2654930T3/es active Active
- 2010-04-12 JP JP2012504924A patent/JP2012523437A/ja active Pending
- 2010-04-12 NO NO10713790A patent/NO2419104T3/no unknown
- 2010-04-12 US US12/758,631 patent/US8404711B2/en not_active Expired - Fee Related
- 2010-04-12 CN CN2010800164976A patent/CN102395371A/zh active Pending
- 2010-04-12 MX MX2011010782A patent/MX2011010782A/es active IP Right Grant
- 2010-04-12 WO PCT/US2010/030760 patent/WO2010120695A2/en not_active Ceased
- 2010-04-12 BR BRPI1013777A patent/BRPI1013777A8/pt not_active IP Right Cessation
- 2010-04-12 KR KR1020117026729A patent/KR20120017421A/ko not_active Ceased
- 2010-04-12 CN CN201610257689.5A patent/CN105832735A/zh active Pending
- 2010-04-12 PL PL10713790T patent/PL2419104T3/pl unknown
- 2010-04-12 EP EP10713790.3A patent/EP2419104B1/en active Active
- 2010-04-12 DK DK10713790.3T patent/DK2419104T3/en active
-
2011
- 2011-10-10 IL IL215660A patent/IL215660A0/en unknown
- 2011-10-12 ZA ZA2011/07490A patent/ZA201107490B/en unknown
-
2013
- 2013-02-20 US US13/771,685 patent/US20140057939A1/en not_active Abandoned
-
2018
- 2018-01-19 CY CY20181100069T patent/CY1119800T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140057939A1 (en) | 2014-02-27 |
| JP2012523437A (ja) | 2012-10-04 |
| CY1119800T1 (el) | 2018-06-27 |
| HRP20180018T1 (hr) | 2018-02-09 |
| BRPI1013777A2 (pt) | 2016-04-05 |
| US8404711B2 (en) | 2013-03-26 |
| KR20120017421A (ko) | 2012-02-28 |
| AU2010236734B2 (en) | 2015-06-11 |
| LT2419104T (lt) | 2018-02-12 |
| IL215660A0 (en) | 2012-01-31 |
| WO2010120695A3 (en) | 2010-12-02 |
| EP2419104B1 (en) | 2017-11-08 |
| NO2419104T3 (enExample) | 2018-04-07 |
| PT2419104T (pt) | 2018-01-31 |
| DK2419104T3 (en) | 2018-02-05 |
| AU2010236734A1 (en) | 2011-11-03 |
| RU2569056C2 (ru) | 2015-11-20 |
| WO2010120695A2 (en) | 2010-10-21 |
| BRPI1013777A8 (pt) | 2017-09-19 |
| EP2419104A2 (en) | 2012-02-22 |
| SMT201800036T1 (it) | 2018-03-08 |
| ZA201107490B (en) | 2012-06-27 |
| US20100261752A1 (en) | 2010-10-14 |
| AU2010236734A8 (en) | 2012-02-16 |
| RU2011146032A (ru) | 2013-05-20 |
| ES2654930T3 (es) | 2018-02-15 |
| CN105832735A (zh) | 2016-08-10 |
| HUE038141T2 (hu) | 2018-10-29 |
| SI2419104T1 (en) | 2018-03-30 |
| CA2758321A1 (en) | 2010-10-21 |
| MX2011010782A (es) | 2012-01-20 |
| CN102395371A (zh) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2419104T (pt) | Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos | |
| PT2467372T (pt) | Tratamento de distúrbios relacionados com bdnf usando laquinimod | |
| EP2293800A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EARLIER DISEASES | |
| IL216140A0 (en) | Egfr inhibitors and methods of treating disorders | |
| ZA201202500B (en) | Use of toll-like receptor and agonist for treating cancer | |
| ZA201001193B (en) | 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders | |
| EP2456868A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SUFFERING OF SUFFERING THROUGH MUSCARIN RECEPTOR ACTIVATION | |
| IL217777A0 (en) | Methods for treatment of pain | |
| SMT201700451T1 (it) | Antagonisti di wnt e metodi di trattamento | |
| IL216281A0 (en) | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors | |
| ZA201201290B (en) | Methods and compositions for treatment of pulmonary fibrotic disorders | |
| IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
| LT2427193T (lt) | Pde7 inhibitoriaus panaudojimas judėjimo sutrikimų gydymui | |
| ZA201106076B (en) | Treatment of insulin-resistant disorders | |
| EP2401561A4 (en) | DEVICE AND METHOD FOR TREATMENT BY CRYOTHERAPY | |
| ZA201203239B (en) | Methods and compositions for rapid treatment of otitis externa | |
| EP2475390A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS | |
| IL217297A0 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
| ZA201202379B (en) | Antagonists of dsgs2 for treatment of cancer | |
| ZA201105514B (en) | Use of deferiprone for treatment and prevention of iron-related eye disorders | |
| BR112013001939A2 (pt) | tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase | |
| HU0900712D0 (en) | New methods and intermediers for the synthesis of ace-inhibitor | |
| IL209658A0 (en) | Compositions and methods for treatment of ear disorders | |
| HK1167106A (en) | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors | |
| HK1177888A (en) | 5-ht4 receptor agonists for the treatment of dementia |